Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)
Clinical trial NCT04009317 · UNKNOWN
Trial details
- NCT number
- NCT04009317
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-08-13
- Primary completion
- 2021-10-30
- Enrollment
- 260
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.